Hengrui Pharma presents 64 research findings at ESMO 2026
Hengrui Pharma has showcased 64 oncology research studies at the ESMO 2026 Congress, featuring multiple oral presentations across various cancer treatment areas.
Chinese pharmaceutical firm Hengrui Pharma disclosed 64 research findings during the European Society for Medical Oncology (ESMO) 2026 Congress. The data set includes three late-breaking abstracts and three rapid oral presentations, highlighting the company’s current focus on clinical development in oncology.
The research spans over ten therapeutic areas within the oncology and supportive care sectors. These findings reflect the company's ongoing efforts to diversify its pipeline and validate existing therapeutic candidates through clinical evidence presented to the international medical community.
Participation in major industry conferences like ESMO serves as a critical indicator for investors and stakeholders regarding a company's R&D productivity. The scope of the presentations underscores Hengrui’s intent to secure a stronger position in global markets by demonstrating efficacy data across a broad range of cancer treatments.